Ads
related to: pulmonary fibrosis stem cell breakthrough- Finding Support
Provide Patients With Access To
Their Own Personalized Care.
- Dosing Information
Offer Your Patients A Dosing
Schedule To Help With Treatment.
- Finding Support
Search results
Results from the WOW.Com Content Network
Drugs granted breakthrough therapy designation (BTD) by the US Food and Drug Administration (FDA). Drugs may be listed more than once since breakthrough therapy can be awarded for multiple indications.
Nintedanib, sold under the brand names Ofev and Vargatef, is an oral medication used for the treatment of idiopathic pulmonary fibrosis and along with other medications for some types of non-small-cell lung cancer.
Pulmonary fibrosis is a condition in which the lungs become scarred over time. [1] Symptoms include shortness of breath , a dry cough, feeling tired, weight loss, and nail clubbing . [ 1 ] Complications may include pulmonary hypertension , respiratory failure , pneumothorax , and lung cancer .
Idiopathic pulmonary fibrosis; Other names: Fibrosing alveolitis, cryptogenic fibrosing alveolitis, diffuse fibrosing alveolitis, usual interstitial pneumonitis, diffuse interstitial pneumonitis: Figure A shows the location of the lungs and airways in the body. The inset image shows a detailed view of the lung's airways and air sacs in cross ...
The long quest for gender parity. For Caltech, a campus of 2,400 undergraduate and graduate students with 47 Nobel awards and more than 50 research centers, the road to gender parity has been long.
Adult stem cells are found throughout the human body in locations known as niches. These cells multiply by cell division to replenish dying cells and regenerate tissue. These cells are essential for recovery from certain forms of cancer such as leukemia, where some treatment plans can involve stem cell transplants. A more recent hypothesis ...
CRISPR is used to edit the cells in order to reduce the chance the patient's body will reject the transplant. On November 17, 2021 CRISPR therapeutics and ViaCyte announced that the Canadian medical agency had approved their request for a clinical trial for VCTX210, a CRISPR-edited stem cell therapy designed to treat type 1 diabetes.
Examples include the injection of stem cells or progenitor cells obtained through directed differentiation (cell therapies); the induction of regeneration by biologically active molecules administered alone or as a secretion by infused cells (immunomodulation therapy); and transplantation of in vitro grown organs and tissues (tissue engineering).
Ads
related to: pulmonary fibrosis stem cell breakthrough